Combined application of hypothermia and medical gases in cerebrovascular diseases

Hao Li1,*, Xin Tan1,*, Qun Xue1,*, Jue-Hua Zhu1,*, Gang Chen2
1 Department of Neurology, the First Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, China
2 Department of Neurosurgery & Brain and Nerve Research Laboratory, the First Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, China

#These authors contributed equally to this work.
*Correspondence to: Qun Xue, PhD, qxue_az@163.com; Jue-Hua Zhu, PhD, zhujuehua0216@suda.edu.cn.
orcid: 0000-0002-7324-7982 (Qun Xue)

Abstract
Cerebrovascular diseases have a heavy burden on society and the family. At present, in the treatment of cerebrovascular diseases, the recognized effective treatment method is a thrombolytic therapy after cerebral infarction, but limited to the time window problem, many patients cannot benefit. Other treatments for cerebrovascular disease are still in the exploration stage. The study found that medical gas and hypothermia have brain protection effects. Further research found that when the two are used in combination, the therapeutic effect has a superimposed effect. This article reviews the current research progress of hypothermia therapy combined with medical gas therapy for cerebrovascular disease.

Key words: hypothermia therapy; medical gas; cerebrovascular diseases; neuroprotection; ischemic stroke; xenon; normobaric hyperoxia
doi: 10.4103/2045-9912.248269
How to cite this article: Li H, Tan X, Xue Q, Zhu JH, Chen G. Combined application of hypothermia and medical gases in cerebrovascular diseases. Med Gas Res. 2018;8(4):172-175.

INTRODUCTION
Cerebrovascular disease is one of the three major causes of death that poses a serious threat to human life. It has high morbidity, disability and mortality.1 At present, the most mature cerebrovascular treatment is revascularization of acute cerebral infarction.2 However, due to the narrow therapeutic time window of thrombolytic therapy and the complications of bleeding, it has great limitations for many stroke patients.3 In this context, neuroprotective treatment has sprung up, and has achieve good results in basic research, becoming a new direction of stroke research. Neuroprotective treatment refers to the protection of brain parenchyma or brain cells, rather than revascularization, and can be used for the treatment of various cerebrovascular diseases.4 Currently, there are several kinds of mechanisms involved in neuroprotective therapy, including ion channel modulators,5 anti-excitotoxic drugs,6 free radical scavengers,7 neurotrophic factors,8 hypothermia therapy (HT),9 ion channel modulators,10 gene therapy and stem cell transplantation.10 In addition, there are some gas researches on brain protection.11 Among them, HT and medical gas therapy are increasingly concerned by researchers because of their convenience, speed and safety.

HT is currently a recognized and effective treatment.12,13 Ischemic brain damage often occurs after cardiac arrest, and hypothermia is an effective treatment to prevent brain damage due to insufficient blood flow and improve brain function.14,15 In 1987, Busto et al.16 first proposed a systemic hypothermia (33–35°C) method for brain protection. The researchers defined a mild to moderate hypothermia at 28–35°C as a sub-hypothermia and found significant therapeutic and protective effects on experimental ischemia and experimental craniocerebral trauma in hypothermia range.17 The mechanism of brain protection includes the following four aspects. Firstly, HT preserves the adenosine triphosphate required for metabolic recovery after cerebral ischemia by reducing energy expenditure18; secondly, it reduces the release of excitatory amino acids and reduce excitatory damage19; thirdly, it reduces the production of free radicals caused by ischemia20; fourthly, it prevents against ischemia-induced inhibition of calcium/calmodulin-dependent protein kinase II and protein kinase C.21 This is a description about the therapeutic effect of hypothermia in the model of cerebral ischemia. In fact, hypothermia has anti-inflammatory and anti-apoptotic effects in all disease models.22,23

Medical gases are widely used in the medical field and provide solutions for a variety of medical needs. Medical gases such as oxygen, helium, xenon,24 and hydrogen have been reported to have potential therapeutic effects and can treat a variety of brain diseases including hypoxia-ischemia, cerebral hemorrhages, and traumatic brain injuries.25 Currently, xenon, which is a noble gas, has been reported to have neuroprotective effects.26 Xenon may protect neurons by antagonizing N-methyl-D-aspartate receptors. Evidence reveals that xenon can provide protection and trophic support to neuron in a direct or indirect way.27 Xenon originally reported to have brain protection in an ischemic model.

EXPERIMENTAL STUDIES
Hypoxic ischemic encephalopathy (HIE) presents an unnoticeable social burden with its high mortality and morbidity rates in the newborn population. HIE causes long-term neurological and behavioral impairment in the developing brain.28 Induced therapeutic hypothermia has certified as an effective neuroprotective strategy for newborns with HIE.29 However, about half of all treated neonates still die or face neurodevelopmental sequelae later in life.30 Studies have shown that
vascular endothelial growth factor is expressed in the injured brain of neonates receiving hypothermia after an ischemic hypoxia event. Studies have shown that when combined with hypothermia and inhaled xenon in treatment of ischemia and hypoxia, it has a synergistic effect and has a protective effect on the brain. Martin et al. used 20% xenon combined with low temperature of 35°C to treat HIE in neonatal rats, which can significantly reduce the average brain area loss compared with single use. The researchers used a nylon thread to ligature the right common carotid artery for 1 hour, followed by ischemia and hypoxia for 90 minutes. After successful modeling, different interventions were found in groups, and no brain protection effect was found by using 20% xenon or 35°C low temperature treatment alone. When the two are used in combination, the volume of cerebral infarction can be significantly reduced. More interestingly, even if the two are not used synchronously, the cerebral infarction volume can be significantly reduced. Hobbs et al. used standard neonatal hypoxic ischemic rat model. A total of 119 rat pups were randomized to juvenile control or experimental groups. Then, the experimental pups underwent left common carotid ligation under anesthesia. The rat pups that survived this hypoxia were randomly divided into four groups to recover for 3 hours at normothermia (NT32°) or hypothermia (HT32°) with or without 50% xenon (Xe30%) in the breathing gas. Afterwards, the rats were tested for early and late behavioral tests. Interestingly, hypothermia alone produced a functional improvement both short- and long-term testing, whereas Xe30% shows only modest functional recovery in long-term behavioral test. Importantly, Xe30% combined with HT32° treatment showed the greatest improvement on both short- and long-term behavioral test. Similarly, the combination produced the greatest improvement in global histopathology scores, a pattern mirrored in the regional scores. So the Xe30%+HT32° combination shows the greatest neuroprotection. Chakkarapani et al. found that 24-hour HT provided 48% neuroprotection. Furthermore, combining 18-hour xenon with 24-hour HT offered 75% neuroprotection. The neuroprotective effects of HT-Xe were additive when administered together. It can significantly reduce histological injury. At the same time, they also found that a better extension of the hypothermia time can significantly reduce the average brain area loss compared with single use. When xenon combined with hypothermia for neonatal asphyxia, the clinical effect is not satisfactory. The dose, timing, and duration of treatment with inhaled xenon might have been suboptimum. Therefore, clinical applications still require a large number of randomized controlled trials to verify.

Oxygen is the basis of all human activities, and is the driving force for the growth and development of life and life activities. From it has been discovered that oxygen can be used in treatment of several kinds of disease, it has been widely used in clinical practice. Importantly, the application of oxygen is no longer limited to a single disease. Many studies have shown that the application of oxygen in cerebrovascular disease has become more and more mature. For oxygen applications, the two current methods are normobaric hyperoxia (NBO) and hyperbaric oxygen. Hyperbaric oxygen can increase the partial pressure of oxygen, the diffusion rate of oxygen, and the effective dispersion distance. Directly improve energy metabolism in the ischemic or penumbra. After increasing the oxygen supply, hyperbaric oxygen has the function of contracting blood vessels, which can reduce total intracranial blood flow and reduce brain edema. In addition, it also has anti-inflammatory, reduces the permeability of the blood-brain barrier, promotes thrombosis absorption, and scavenges free radicals. NBO is a treatment method in which a mask or an oxygen-absorbing hood is continuously inhaled in a normal pressure environment or a high-oxygen chamber is not pressurized, and a specific oxygen-absorbing device is used to absorb high-concentration oxygen. Studies have shown that there are similarities in the therapeutic mechanisms of NBO and hyperbaric oxygen. NBO can increase the blood oxygen partial pressure and blood oxygen content of the ischemic penumbra brain tissue to improve hypoxia. In recent years, it has been found that hypothermia combined with oxygen therapy has a better effect on cerebrovascular diseases. Cai et al. also found that NBO and hypothermia treatment can produce better brain protection.

Clinical Studies
At present, the combination of hypothermia and medical gas has shown good application prospects in basic experiments, but the results of clinical studies are rare. Recent studies have found that when combined with hypothermia for treatment of neonatal asphyxia, the effect is not satisfactory, and side effects occur in the application of xenon. Azzopardi et al. enrolled 92 infants, 46 of whom were randomly assigned to cooling only and 46 to xenon plus cooling. They performed a magnetic resonance assessment of the treated newborn. However, they noted no significant differences in lactate to N-acetyl aspartate ratio in the thalamus or fractional anisotropy in the posterior limb of the internal capsule between the two groups. The researchers speculated that the reason for the unsatisfactory clinical trial
results may be due to the difference in the optimal time point and duration of the intervention method for the human body and the experimental animals. Researchers believed that the timing, dose, and duration of treatment with inhaled xenon might have been suboptimum. In addition, given the safety of clinical use, a large number of clinical randomized controlled trials are still needed to verify its effects. The current animal experimental protocol suggests that the combination of early hypothermia and delayed medical gas therapy is neuroprotection.44 Furthermore, in clinical studies, the time points for the combination of hypothermia and medical gases, and duration of hypothermia and medical gases still require further experimental results to verify.

Conclusion

The combination of hypothermia and medical gas has shown great application prospects. The current studies mainly focused on the combination of hypothermia and xenon or oxygen, and have achieved gratifying results. However, there are still many aspects worth exploring such as the effectiveness of the combination of hypothermia and other medical gas. Further researches especially larger clinical trials are required to validate its effectiveness and guide its specific application.

Table 1: Studies regarding the combined use of hypothermia and medical gas for cerebrovascular disease

| Reference          | Year | Animal       | Model       | Results                                                                 |
|--------------------|------|--------------|-------------|-------------------------------------------------------------------------|
| Martin et al. 33   | 2007 | Sprague-Dawley rat | HIE        | Xe<sub>sc</sub>, combined with low temperature of 35°C can significantly reduce the volume of cerebral infarction compared with single use. |
| Hobbs et al. 34    | 2008 | Rat          | HIE         | The Xe<sub>sc</sub> HT<sub>sc</sub> combination shows the greatest neuroprotection. Xe<sub>sc</sub> combined with HT<sub>sc</sub> treatment showed the greatest improvement on both short- and long-term behavioral test. |
| Chakkarapani et al.35 | 2009 | Pig          | HIE         | The neuroprotective effects of HT-Xe were additive when administered. together. It can significantly reduce histological injury. |
| Cai et al. 33      | 2016 | Sprague-Dawley rat | MCAO       | The combination of NBO and HT can reduce the damage level of neurological deficits and infract volume. In addition, it can be better reduced the level of LDH. |
| Wada et al. 44     | 2006 | Mongolian gerbils  | BI         | The hypothermia plus hyperbaric oxygenation group could significantly reduce the cell death in the hippocampal CA1 region. |

Note: MCAO: Middle cerebral artery occlusion; HIE: hypoxic ischemic encephalopathy; BI: brain ischemic; Xe: xenon; HT: hypothermia therapy; NBO: normobaric hyperoxia; LDH: lactate dehydrogenase.

REFERENCES

1. Donnan GA, Fisher M, Macleod M, Davis SM. Stroke. Lancet. 2008;371:1612-1623.
2. Lapchak PA. Critical early thrombolytic and endovascular reperfusion therapy for acute ischemic stroke victims: a call for adjunct neuroprotection. Transl Stroke Res. 2015;6:345-354.
3. Prabhakaran S, Ruff I, Bernstein RA. Acute stroke intervention: a systematic review. JAMA. 2015;313:1451-1462.
4. Jain KK. Neuroprotection in cerebrovascular disease. Expert Opin Investig Drugs. 2006;9:695-711.
5. Waszkiewicz AM, Gunia A, Szkarańek S, Sloczyńska K, Krupińska S, Murona H. Ion channels as drug targets in central nervous system disorders. Curr Med Chem. 2013;20:1241-1285.
6. Gentile A, Musella A, De Vito F, et al. Laquinimod ameliorates excitotoxic damage by regulating glutamate re-uptake. J Neuroinflammation. 2018;15:5.
7. Fujiwara N, Som AT, Pham LD, et al. A free radical scavenger edaravone suppresses systemic inflammatory responses in a rat transient focal ischemia model. Neurosci Lett. 2016;633:7-13.
8. Cobianchi S, Arbat-Plana A, Lopez-Alvarez VM, Navarro X. Neurorprotective effects of exercise treatments after injury: the dual role of neurotrophic factors. Curr Neuropharmacol. 2017;15:495-518.
9. Ma H, Sinha B, Pandya RS, et al. Therapeutic hypothermia as a neuroprotective strategy in neonatal hypoxic-ischemic brain injury and traumatic brain injury. Curr Mol Med. 2012;12:1282-1296.
10. Marsh SE, Blurton-Jones M. Neural stem cell therapy for neurodegenerative disorders: The role of neuroprotective support. Neurochem Int. 2017;106:94-100.
11. Ostrowski RP, Pucko EB. Research of medical gases in Poland. Med Gas Res. 2013;3:17.
12. Yanamoto H, Nagata I, Nakahara I, Tohnai N, Zhang Z, Kikuchi H. Combination of intraischemic and postischemic hypothermia provides potent and persistent neuroprotection against temporary focal ischemia in rats. Stroke. 1999;30:2720-2726.
13. Schwab S, Spranger M, Aschoff A, Steiner T, Hacke W. Brain temperature monitoring and modulation in patients with severe MCA infarction. Neurology. 1997;48:762-767.
14. Ahmed AI, Bullock MR, Dietrich WD. Hypothermia in traumatic brain injury. Neurosurg Clin N Am. 2016;27:489-497.
15. Rochaferreira E, Vincent A, Bright S, Peebles DM, Hristova M. The duration of hypothermia affects short-term neuroprotection in a mouse model of neonatal hypoxic ischaemic injury. PLoS One. 2018;13:e0199890.
16. Bustro R, Dietrich WD, Globus MY, Valdés I, Scheinberg P, Ginsberg MD. Small differences in intraischemic brain temperature critically determine the extent of ischemic neuronal injury. J Cereb Blood Flow Metab. 1987;7:729-738.
17. Jiang JY, Yang XF. Current status of cerebral protection with mild-to-moderate hypothermia after traumatic brain injury. Curr Opin Crit Care. 2007;13:153-155.
18. O’Brien FE, Iwata O, Thornton JS, et al. Delayed whole-body cooling to 33 or 35 degrees C and the development of impaired energy generation consequential to transient cerebral hypoxia-ischemia in the newborn piglet. Pediatrics. 2006;117:1549-1559.
19. Mueller-Burke D, Koehler RC, Martin LJ. Rapid NMDA receptor phosphorylation and oxidative stress precede striatal neurodegeneration after hypoxic ischemia in newborn mice and are attenuated with hypothermia. *Int J Dev Neurosci.* 2008;26:67-76.

20. Perrone S, Szabó M, Bellieni CV, et al. Whole body hypothermia and oxidative stress in babies with hypoxic-ischemic brain injury. *Pediatr Neurol.* 2010;43:236-240.

21. Sui LS, Han F, Guo YW, et al. Time course of calpain activity changes in rat neurons following fluid percussion injury and the interventional effect of mild hypothermia. *Nan Fang Yi Ke Da Xue Xue Bao.* 2007;27:1149-1151.

22. Andresen M, Gazmuri J, Marin A, Regueira T, Rovegno M. Therapeutic hypothermia for acute brain injuries. *Scand J Trauma Resusc Emerg Med.* 2015; 23:42.

23. Lee JH, Wei ZZ, Cao W, et al. Regulation of therapeutic hypothermia on inflammatory cytokines, microglia polarization, migration and functional recovery after ischemic stroke in mice. *Neurobiol Dis.* 2016;96:248-260.

24. Levaur J, Lemaire M, Pype J, Le Nogue D, Hirsch EC, Michel PP. Xenon-mediated neuroprotection in response to sustained, low level excitotoxic stress. *Cell Death Discov.* 2016;2:16018.

25. Szafarski JP, Griffith J, Vannest J, et al. A feasibility study of combined intermittent theta burst stimulation and modified constraint-induced aphasia therapy in chronic post-stroke aphasia. *Restor Neurol Neurosci.* 2018;36:503-518.

26. Alam A, Suen KC, Hana Z, Sanders RD, Maze M, Ma D. Neuroprotection and neurotoxicity in the developing brain: an update on the effects of dexamethasone and xenon. *Neurotoxicol Teratol.* 2017;60:102-116.

27. Lavau J, Le ND, Lemaire M, et al. The noble gas xenon provides protection and trophic stimulation to midbrain dopamine neurons. *J Neurochem.* 2017;142:14-28.

28. Yildiz EP, Ekici B, Tatlı B. Neonatal hypoxic ischemic encephalopathy: an update on disease pathogenesis and treatment. *Expert Rev Neurother.* 2017;17:449-459.

29. Meadams RM, Juul SE. Neonatal encephalopathy: update on therapeutic hypothermia and other novel therapeutics. *Clin Perinatol.* 2016;43:485-500.

30. Jacobs SE, Berg M, Hunt R, Tarnow-Mordi WO, Inder TE, Davis PG. Cooling for newborns with hypoxic ischaemic encephalopathy. *Cochrane Database Syst Rev.* 2013;1:CD003311.

31. Zhao K, Li R, Bi S, et al. Combination of mild therapeutic hypothermia and adipose-derived stem cells for ischemic brain injury. *Neural Regen Res.* 2018;13:1759-1770.

32. Martin JL, Ma D, Hossain M, et al. Asynchronous administration of xenon and hypothermia significantly reduces brain infarction in the neonatal rat. *Br J Anaesth.* 2007;98:236-240.

33. Hobbs C, Thoresen M, Tucker A, Aquilina K, Chakkarapani E, Dingley J. Xenon and hypothermia combine additively, offering long-term functional and histopathologic neuroprotection after neonatal hypoxia/ischemia. *Stroke.* 2008;39:1307-1313.

34. Chakkarapani E, Dingley J, Liu X, et al. Xenon enhances hypothermic neuroprotection in asphyxiated newborn pigs. *Ann Neurol.* 2010;68:330-3341.

35. Azzopardi D, Robertson NJ, Bainbridge A, et al. Moderate hypothermia within 6 h of birth plus inhaled xenon versus moderate hypothermia alone after birth asphyxia (TOBY-Xe): a proof-of-concept, open-label, randomised controlled trial. *Lancet Neurol.* 2016;15:145-153.

36. Heffner JE. The story of oxygen. *Respir Care.* 2013;58:18-31.

37. Liska GM, Lippert T, Russo E, Nieves N, Borlongan CV. A dual role for hyperbaric oxygen in stroke neuroprotection: preconditioning of the brain and stem cells. *Cord Med.* 2018;1:151-166.

38. Fang J, Hongling LI, Guanglei LI, Wang L. Effect of hyperbaric oxygen preconditioning on peri-hemorrhagic focal edema and aquaporin-4 expression. *Exp Ther Med.* 2015;10:699-704.

39. Wang F, Wang Y, Sun T, Yu HL. Hyperbaric oxygen therapy for the treatment of traumatic brain injury: a meta-analysis. *Neural Sci.* 2016;37:693-701.

40. Xy X, Ji R, Wei R, Yin B, He F, Luo B. The efficacy of hyperbaric oxygen therapy on middle cerebral artery occlusion in animal studies: ameta-analysis. *PLoS One.* 2016;11:e0148324.

41. Mazdeh M, Taher A, Torabian S, Seifrad S. Effects of normobaric hyperoxia in severe acute stroke: a randomized controlled clinical trial study. *Acta Med Iran.* 2015;53:676-680.

42. Cai L, Stevenson J, Peng C, et al. Adjuvant therapies using normobaric oxygen with hypothermia or ethanol for reducing hyperglycolysis in thromboembolic cerebral ischemia. *Neuroscience.* 2016;318:45-57.

43. Wada K, Nishi D, Kitamura T, et al. Hyperbaric oxygenation therapy enhances the protective effect of moderate hypothermia against forebrain ischemia in the gerbil hippocampus. *Undersea Hyperb Med.* 2006;33:399-405.

44. Liu X, Dingley J, Scullbrown E, Thoresen M. Adding 5 h delayed xenon to delayed hypothermia treatment improves long-term function in neonatal rats surviving to adulthood. *Pediatr Res.* 2015;77:779-783.

Received: 2018-08-28
Accepted: 2018-11-06